- Home
- SCYX vs KRON Comparison
SCYX vs KRON Comparison
Compare SCYX & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- KRON
- Stock Information
- Founded
- SCYX 1999
- KRON 2017
- Country
- SCYX United States
- KRON United States
- Employees
- SCYX N/A
- KRON N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- KRON Medicinal Chemicals and Botanical Products
- Sector
- SCYX Health Care
- KRON Health Care
- Exchange
- SCYX Nasdaq
- KRON Nasdaq
- Market Cap
- SCYX 50.3M
- KRON 60.3M
- IPO Year
- SCYX 2014
- KRON 2020
- Fundamental
- Price
- SCYX $1.18
- KRON $0.91
- Analyst Decision
- SCYX Buy
- KRON Buy
- Analyst Count
- SCYX 1
- KRON 3
- Target Price
- SCYX N/A
- KRON $1.63
- AVG Volume (30 Days)
- SCYX 165.3K
- KRON 173.3K
- Earning Date
- SCYX 11-06-2024
- KRON 11-13-2024
- Dividend Yield
- SCYX N/A
- KRON N/A
- EPS Growth
- SCYX N/A
- KRON N/A
- EPS
- SCYX N/A
- KRON N/A
- Revenue
- SCYX $8,566,000.00
- KRON $9,864,000.00
- Revenue This Year
- SCYX N/A
- KRON $52.58
- Revenue Next Year
- SCYX $145.59
- KRON N/A
- P/E Ratio
- SCYX N/A
- KRON N/A
- Revenue Growth
- SCYX N/A
- KRON 146.56
- 52 Week Low
- SCYX $1.15
- KRON $0.69
- 52 Week High
- SCYX $3.07
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- SCYX 28.95
- KRON 49.45
- Support Level
- SCYX $1.25
- KRON $0.84
- Resistance Level
- SCYX $1.37
- KRON $0.88
- Average True Range (ATR)
- SCYX 0.06
- KRON 0.05
- MACD
- SCYX -0.01
- KRON 0.00
- Stochastic Oscillator
- SCYX 9.26
- KRON 58.17
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.